

Attorney Docket No: 23546-07724US

Client Ref: RTS-0333

USSN: 10/008,789

AMENDMENTS TO THE CLAIMS

1. (currently amended) A compound 8 to 50 nucleobases in length targeted to nucleobases 259 through 1586 of the coding region of the 5' untranslated region, the start codon region, the coding region, the stop codon region, or the 3' untranslated region of a nucleic acid molecule of SEQ ID NO:3 encoding thyroid hormone receptor interactor 6, ~~with the proviso of not including nucleobases 1608 through 1642 of SEQ ID NO:3~~, wherein said compound specifically hybridizes with ~~one of said regions~~ and inhibits the expression of thyroid hormone receptor interactor 6.

2. (original) The compound of claim 1 which is an antisense oligonucleotide.

3. (canceled)

4. (original): The compound of claim 2, wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

5. (original): The compound of claim 4, wherein the modified internucleoside linkage is a phosphorothioate linkage.

6. (original): The compound of claim 2, wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

7. (original): The compound of claim 6, wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

8. (original): The compound of claim 2, wherein the antisense oligonucleotide comprises at least one modified nucleobase.

9. (original): The compound of claim 8, wherein the modified nucleobase is a 5-methylcytosine.

10. (original): The compound of claim 2, wherein the antisense oligonucleotide is a chimeric oligonucleotide.

11. (canceled)

12. (original): A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

Attorney Docket No: 23546-07724US
Client Ref: RTS-0333
USSN: 10/008,789

13. (original): The composition of claim 12 further comprising a colloidal dispersion system.

14. (original): The composition of claim 12, wherein the compound is an antisense oligonucleotide.

15. (previously presented): A method of inhibiting the expression of thyroid hormone receptor interactor 6 in cells or tissues comprising contacting said cells or tissues *in vitro* with the antisense compound of claim 1 so that expression of thyroid hormone receptor interactor 6 is inhibited.

16-18. (canceled)

19. (currently amended): The compound of claim 1 targeted to a nucleic acid molecule encoding thyroid hormone receptor interactor 6, wherein said compound specifically hybridizes with and differentially inhibits by at least 41% the expression of a first variant of thyroid hormone receptor interactor 6, TRIP6-I (SEQ ID NO:3) relative to a second variant of thyroid hormone receptor interactor 6, TRIP6-II (SEQ ID NO:11). ~~one or more of the variants of thyroid hormone receptor interactor 6 relative to the remaining variants of thyroid hormone receptor interactor 6.~~

20. (previously presented): The compound of claim 19 targeted to a nucleic acid molecule encoding thyroid hormone receptor interactor 6, wherein said compound hybridizes with and specifically inhibits the expression of TRIP6-I (SEQ ID NO:3).

21. (withdrawn): The compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 13, 14, 16, 17, 18, 19, 22, 23, 25, 26, 27, 29, 30, 31, 33, 35, 40, 41, 43, 45, 46, 47, 48, 49, 51, 53, 54, 55, 56, 57, 59, 60, 61, 64, 65, 66, 67, 68, 69, 70, 71, 72, 74, 76, 78, 81, 84, 87 or 88.

22. (withdrawn): The compound of claim 21, wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO:22.